Vraylar Approved to Treat Depressive Episodes Associated With Bipolar I Disorder
The FDA has approved the use of Vraylar (cariprazine; Allergan) to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
All articles by Brian Park, PharmD
FDA Grants Breakthrough Status to a Digital Intervention Tx for Nightmares in PTSD Patients
The Food and Drug Administration (FDA) has granted Breakthrough Status designation to NightWare (NightWare, Inc.), a digital intervention therapy that measures and treats nightmares in patients with post traumatic stress disorder (PTSD).
Next post in PTSD trauma and stressor-related
